drugset / Trial / NCT03267576

An Efficacy Study of Canagliflozin or Sitagliptin to Determine Glucose Variability in Mexican Participants With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin

NCT03267576

Phase 4 Completed 64 enrolled Janssen Research & Development, LLC
RandomizedCrossoverDouble-blindTreatment

Summary

The main purpose of this study is to assess the effects of 4 weeks each of daily treatment with canagliflozin 300 milligram (mg) versus sitagliptin 100 mg as treatment adjuncts to metformin (at stable dosages) on intrapatient glycemic coefficient of variation (CV), expressed as a ratio percentage of standard deviation (SD) to mean glucose levels.

Timeline

Start
2017-10-27
Primary completion
2018-10-01
Completion
2018-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject CANAGLIFLOZIN ANHYDROUS Small molecule 300 mg Oral
Subject Sitagliptin Small molecule 100 mg Oral
Background Metformin Small molecule 1500 mg Oral